Research summary
Research HubGHRP-2
Clinical — 10 studies
GHRP-2 is a synthetic hexapeptide investigated for its ability to stimulate growth hormone secretion via ghrelin receptor pathways.
Being studied for
- Growth hormone release
- Appetite and ghrelin signaling research
Published Research
Evidence profile
Controlled human evidence
10 cited publications · 4 primary trials
Findings below belong to the studies that reported them. They describe the material and conditions those authors used, not this product, and not an outcome to expect.
Supporting evidence
The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone
Van den Berghe G et al. · Clinical endocrinology · 2002
The study reportedCoadministration of GHRP-2, TRH and GnRH reactivated the GH, TSH and LH axes in prolonged critically ill men and evoked beneficial metabolic effects which were absent with GHRP-2 infusion alone and only partially present with GHRP-2 + TRH.
Synergy of L-arginine and GHRP-2 stimulation of growth hormone in men and women: modulation by exercise
Wideman L et al. · American journal of physiology. Regulatory, integrative and comparative physiology · 2000
The study reportedExercise potentiated the individual stimulatory actions of A and G, while blunting the relative magnitude of the synergistic (supra-additive) interaction observed at rest.
Growth hormone-releasing peptide-2 infusion synchronizes growth hormone, thyrotrophin and prolactin release in prolonged critical illness
Van den Berghe G et al. · European journal of endocrinology · 1999
The study reportedThe nocturnal GH, TSH and PRL secretory patterns during prolonged critical illness are herewith further characterized to include loss of synchrony among GH, TSH and PRL release.
Treatment effects of intranasal growth hormone releasing peptide-2 in children with short stature
Pihoker C et al. · The Journal of endocrinology · 1997
The study reportedGHBP concentrations rose significantly, from 439 +/- 63 pmol/l to 688 +/- 48 pmol/l. In this study, intranasal GHRP-2 administration was well tolerated, and produced a modest but significant increase in growth velocity.
Additional indexed literature (6)
- Clinical · Mechanistic studyAssessment of anterior pituitary reserve capacity based on growth hormone response to growth hormone-releasing peptide-2 test in the elderly
Teramoto S et al. · Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2023 · PMID 37295337
- Clinical · Mechanistic studyPreoperative growth hormone (GH) peak values during a GH releasing peptide-2 test reflect the severity of hypopituitarism and the postoperative recovery of GH secretion in patients with non-functioning pituitary adenomas
Soga A et al. · Endocrine journal · 2020 · PMID 31776295
- Clinical · Mechanistic studyEvaluation of growth hormone-releasing peptide-2 for diagnosis of thyrotropin-producing pituitary adenomas
Kageyama K et al. · Endocrine journal · 2018 · PMID 29973439
- Preclinical · Mechanistic studyGrowth Hormone Releasing Peptide-2 Attenuation of Protein Kinase C-Induced Inflammation in Human Ovarian Granulosa Cells
Chao YN et al. · International journal of molecular sciences · 2016 · PMID 27548147
- Preclinical · Mechanistic studyDetermination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin
Semenistaya E et al. · Drug testing and analysis · 2015 · PMID 25869809
- Preclinical · Mechanistic studySynthesis of Mono-PEGylated Growth Hormone Releasing Peptide-2 and Investigation of its Biological Activity
Hu X et al. · AAPS PharmSciTech · 2015 · PMID 25761386
Published studies summarised here concern the specific investigational or pharmaceutical materials and study conditions described by their authors. Their findings are not performance claims for Cobalt Peptides material. Citations verified against PubMed on 2026-08-09.
Notice
All information on this page is provided strictly for laboratory research and educational purposes only.